Skip to main content

4 Result(s)

within Protocol Remove this filter Irving L. Weissman Remove this filter

and

  1. No Access

    Protocol

    Immunogenicity of In Vitro Maintained and Matured Populations: Potential Barriers to Engraftment of Human Pluripotent Stem Cell Derivatives

    The potential to develop into any cell type makes human pluripotent stem cells (hPSCs) one of the most promising sources for regenerative treatments. Hurdles to their clinical applications include (1) formatio...

    Chad Tang, Irving L. Weissman, Micha Drukker in Embryonic Stem Cell Immunobiology (2013)

  2. No Access

    Protocol

    Generation of a Monoclonal Antibody Library Against Human Embryonic Stem Cells

    Differentiated cell types derived from human embryonic stem cells (hESCs) may serve in the future to treat various human diseases and to model early human embryonic development in vitro. Fulfilling this potent...

    Micha Drukker, Christina Muscat, Irving L. Weissman in Stem Cell Assays (2007)

  3. No Access

    Protocol

    Retroviral Transduction of FACS-Purified Hematopoietic Stem Cells

    Since the mid-1980s, murine retroviral vectors have been used extensively by a number of investigators to clonally mark and genetically modify primitive hematopoietic stem cells (HSC) (1,2). During this period, b...

    Claudiu V. Cotta, C. Weissman, Irving L. Weissman… in Hematopoietic Stem Cell Protocols (2002)

  4. No Access

    Protocol

    Intrathymic Injection for Analysis of T-Cell Progenitor Activity

    Within our field, improvement in fluorescence-activated cell sorting (FACS) and molecular technologies has led to various types of correlative studies that imply the developmental sequence and subsequent emigr...

    Libuse Jerabek, Irving L. Weissman in Hematopoietic Stem Cell Protocols (2002)